eXoZymes, Inc. (NASDAQ:EXOZ) — Market Cap & Net Worth
Market Cap & Net Worth: eXoZymes, Inc. (EXOZ)
eXoZymes, Inc. (NASDAQ:EXOZ) has a market capitalization of $53.67 Million ($53.67 Million) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #21704 globally and #4778 in its home market, demonstrating a -18.85% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying eXoZymes, Inc.'s stock price $6.33 by its total outstanding shares 8478992 (8.48 Million). Review eXoZymes, Inc. (EXOZ) total liabilities to assess the company's total debt and financial obligations.
eXoZymes, Inc. Market Cap History: 2025 to 2026
eXoZymes, Inc.'s market capitalization history from 2025 to 2026. Data shows growth from $92.42 Million to $53.67 Million (0.00% CAGR).
Index Memberships
eXoZymes, Inc. is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.00% | #621 of 976 |
Weight: eXoZymes, Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
eXoZymes, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how eXoZymes, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of EXOZ by Market Capitalization
Companies near eXoZymes, Inc. in the global market cap rankings as of June 18, 2026.
Key companies related to eXoZymes, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
eXoZymes, Inc. Historical Marketcap From 2025 to 2026
Between 2025 and today, eXoZymes, Inc.'s market cap moved from $92.42 Million to $ 53.67 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $53.67 Million | -41.93% |
| 2025 | $92.42 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of eXoZymes, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $53.67 Million USD |
| MoneyControl | $53.67 Million USD |
| MarketWatch | $53.67 Million USD |
| marketcap.company | $53.67 Million USD |
| Reuters | $53.67 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About eXoZymes, Inc.
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.